€247.4m market cap
€19.52 last close
Carmat is developing a biocompatible, artificial heart to satisfy the lack of donor hearts available for terminal heart failure patients. The development process combines the expertise of a wide range of technical and medical experts.
Investment summary
Carmat is enrolling its 20-patient study for its artificial heart in France, Kazakhstan, the Czech Republic and Denmark. Data from the first cohort of 10 patients indicated that 70% of the patients within that cohort reached the primary endpoint of six-month survival with the bioprosthesis or a successful heart transplant within six months of the device implant. In addition, Carmat recently received FDA approval to begin an early feasibility study in the US in 10 transplant-eligible patients. The company expects to start enrolment in the trial in Q420.
Y/E Dec |
Revenue (€m) |
EBITDA (€m) |
PBT (€m) |
EPS (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2018A | 0.7 | (41.8) | (43.7) | (454.43) | N/A | N/A |
| 2019A | 0.7 | (41.2) | (44.2) | (388.00) | N/A | N/A |
| 2020E | 7.5 | (45.5) | (49.0) | (384.30) | N/A | N/A |
| 2021E | N/A | N/A | N/A | N/A | N/A | N/A |
Industry outlook
The Carmat artificial heart is being developed as a permanent replacement or destination therapy for chronic biventricular heart failure or acute myocardial infarction patients who do not have access to a human donor heart. Despite the high EU and US prevalence of stage IV heart failure (c 500,000 patients), the shortfall in donor hearts is such that only about 3,800 human heart transplants were performed in Europe and the US in 2013.
Last updated on 22/09/2020
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (€m) | 25.9 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Stéphane Piat | CEO |
| Pascale d'Arbonneau | CFO |
| Piet Jansen | Chief Medical Officer |
You may also be interested in…
- 4SC
- Abliva
- Acacia Pharma
- Acarix
- ADL Bionatur Solutions
- Adocia
- ASIT biotech
- Basilea Pharmaceutica
- BioPorto Diagnostics
- Bonesupport
- Brighter
- Cantargia
- Celyad
- Deinove
- Formycon
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- Kiadis Pharma
- Laboratorios Farmacéuticos ROVI
- MagForce
- Medigene
- MOLOGEN
- Nanobiotix
- Newron Pharmaceuticals
- Nuevolution
- Oncology Venture
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Photocure
- Pixium Vision
- Probiodrug
- Quantum Genomics
- RhoVac
- Ryvu Therapeutics
- Targovax
- Transgene
- TxCell
- Xbrane Biopharma